| Mechanism | Surface bioelectrical recording & photoplethysmography |
| Key Spec | Lead vectors, sampling rate, continuous vs. event recording |
| Protocol | Device selection based on symptom frequency and risk |
| FDA Class | Class II Diagnostic Device |
| Entry Cost | $100 – $3,000 (clinical service dependent) |
Ambulatory electrocardiographic (ECG) and rhythm monitoring encompasses a spectrum of diagnostic modalities designed to record and analyze cardiac electrical activity outside standard clinical environments [1][2]. It is a vital clinical tool for identifying transient arrhythmias, evaluating syncope, managing conduction disorders, and integrating digital mobile health (mHealth) biomarkers into clinical care pathways [1:1][3][2:1][4]. While these outpatient rhythm modalities are evaluated in patients who may also undergo complementary cardiovascular assessments—such as home blood pressure monitoring or clinical fitness evaluation via VO2 max testing—the guidelines by the ISHNE-HRS [2:2] and the ACC/AHA/HRS [5] focus strictly on cardiac rhythm and conduction parameters themselves.
Ambulatory ECG monitoring is highly effective at detecting silent, transient, and paroxysmal cardiac arrhythmias. While systematic mass screening of asymptomatic, average-risk older adults lacks sufficient evidence of net benefit according to the USPSTF [10], and continuous monitoring in older adults with at least one additional stroke risk factor did not significantly reduce stroke risk overall in the LOOP trial ([11], [12]), continuous monitoring is highly effective for detecting atrial fibrillation in post-cryptogenic stroke cohorts [8:1]. Although a meta-analysis of clinical trials of continuous monitoring in patients with a history of stroke did not demonstrate a significant reduction in recurrent stroke risk [6:1], screening has shown stroke-prevention benefits in specific high-risk subgroups identified by biomarkers, blood pressure, or genetic risk [13][14][15][16].
Ambulatory ECG monitors record surface bioelectrical potentials generated by cardiac depolarization and repolarization.
The clinical utility of ambulatory ECG monitoring is highly dependent on signal quality. Unlike standard in-clinic 12-lead ECGs recorded in a controlled, motionless environment, outpatient recorders must acquire cardiac potentials while the patient is actively moving [2:8].
| Specification | Standard Holter | Extended Continuous Patch | Mobile Cardiac Outpatient Telemetry (MCOT) | Implantable Loop Recorder (ILR) |
|---|---|---|---|---|
| Duration of Monitoring | 24 to 48 Hours | 7 to 14 Days | 14 to 30 Days | 3 to 5 Years |
| Signal Modality | Surface ECG (3-12 leads) | Surface ECG (1-3 leads) | Surface ECG (1-3 leads with cellular transmission) | Subcutaneous ECG (1 vector) |
| Data Transmission | Retrospective (store-on-board) | Retrospective (store-on-board) | Real-time (cellular telemetry) | Automatic cellular (daily home transmitter) |
| Lead Configuration | Adhesive electrodes with wire cables | Single integrated adhesive patch | Adhesive patch or wires with transmitter | Subcutaneous metal contacts |
| Arrhythmia Detection | Human reviewed after device return | Human reviewed after device return | Machine-learning algorithms with near real-time technician review | Auto-trigger algorithms (R-R interval irregularity and incoherence) [17:2] |
Selecting the appropriate ambulatory ECG tool depends on symptom frequency and clinical indication [1:5][2:11]:
| Parameter | Standard Holter | Extended External Patch | Mobile Telemetry (MCOT) | Implantable Loop Recorder |
|---|---|---|---|---|
| Ideal Duration | 24 to 48 Hours | 7 to 14 Days | 14 to 30 Days | 3 to 5 Years |
| Indication | Daily symptoms, rate control assessment | Weekly/intermittent symptoms, post-stroke screening | Real-time surveillance, highly symptomatic events | Infrequent syncopic episodes, cryptogenic stroke [8:3] |
| Lead Count | 3 to 12 Leads | 1 to 3 Leads | 1 to 3 Leads | 1 (subcutaneous vector) |
| Patient Effort | High (diaries, cables) | Low (single water-resistant patch) | Low to Moderate | None (continuous automatic) |
| Outcome / Goal | Effect* | Consistency** | Evidence Quality | Trials / Studies *** | Notes (population, duration, dose / monitoring protocol) |
|---|---|---|---|---|---|
| Arrhythmia Detection (Wearable PPG) | ▲▲ | High | High | Apple Heart Study (419,297 users) [7:3], Nguyen 2025 [19], Turakhia 2019 [20] | Passive smartwatch PPG tracking achieves an 84% positive predictive value for concurrent AF during subsequent irregular pulse notifications, with 34% of participants confirmed to have AF during follow-up ECG patch monitoring [7:4]. |
| Arrhythmia Detection (Post-Stroke ICM) | ▲▲▲ | High | High | CRYSTAL AF [8:4] | Continuous subcutaneous insertable cardiac monitors (ICM) achieve a significant increase in AF detection (12.4% at 1 year) compared to conventional follow-up (2.0%) in post-stroke cohorts [8:5]. |
| Stroke Prevention (Systematic Screening) | ▲ | Moderate | High | STROKESTOP [21], LOOP [11:1], USPSTF 2022 [10:1] | Systematic population-based screening in older cohorts using intermittent ECGs for 14 days reduces a primary combined endpoint [21:1]. In the overall LOOP trial, continuous loop recorder screening did not significantly reduce stroke risk overall [11:2]. |
| Targeted Stroke Prevention (High-Risk Subgroups) | ▲▲ | High | High | LOOP Substudies [13:1][14:1][15:1][22][16:1] | Continuous ILR screening yields significant stroke risk reductions in targeted high-risk subgroups: NT-proBNP above median (HR 0.60) [13:2], SBP ≥ 150 mmHg (HR 0.56) [15:2], low TSH (HR 0.52) [16:2], lower LA contraction strain [22:1], and elevated genetic risk [14:2]. |
▲ = slight increase, ▲▲ = moderate increase, ▲▲▲ = strong increase, ▼ = slight decrease, ▼▼ = moderate decrease, ▼▼▼ = strong decrease.[^1]) in the "Notes" column for every single row. If you claim a result, you must link the specific Meta-Analysis or Key RCT that proves it.Ischemic strokes are classified as cryptogenic—where the cause of the stroke remains uncertain despite standard diagnostic evaluation—in 20% to 40% of cases [8:6], or approximately 30% in some clinical cohorts [23]. The identification of underlying paroxysmal atrial fibrillation is critical because secondary prevention relies on anticoagulants [8:7].
Secondary analyses of the LOOP trial have identified specific clinical and biomarker-based subgroups that derive substantial stroke-reduction benefit from continuous ILR screening:
While ambulatory monitoring is predominantly an outpatient diagnostic procedure, it frequently registers high-risk, life-threatening dysrhythmias that demand immediate clinical escalation:
Long-term skin-electrode interface poses a common clinical challenge:
The integration of digital mobile health (mHealth) tools and remote transmission systems in outpatient cardiac monitoring facilitates timely clinical decisions, but also introduces operational challenges:
Ambulatory ECG monitoring devices must be carefully evaluated for clinical appropriateness and diagnostic accuracy:
While ambulatory ECG and digital health monitoring offer powerful capabilities for arrhythmia detection, their real-world clinical utility is heavily shaped by socioeconomic and geographic disparities in access and uptake [32].
A smartwatch ECG provides an intermittent, single-lead snapshot of cardiac rhythm, typically initiated by the user. In contrast, a medical-grade ECG patch is a continuous adhesive chest sensor that records every single heartbeat over several days to weeks, capturing paroxysmal arrhythmias during daily activities and sleep [18:1].
No. Standard clinical practice guidelines and studies establish that consumer-wearable notifications are screening alerts, not definitive diagnoses [7:5]. Any wearable alert must be verified using medical-grade ambulatory ECG monitoring or a standard clinical ECG before initiating chronic therapies [7:6][1:9][2:26].
Device selection is commonly tailored based on symptom frequency [1:10][2:27]. If symptoms occur daily, a 24-to-48 hour continuous Holter monitor is utilized [1:11][2:28]. If symptoms are highly infrequent (occurring weeks or months apart), a continuous subcutaneous ILR is preferred to capture transient events over extended surveillance periods, such as the median 5.4-year follow-up in the LOOP study [11:6].
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2024;45(39):3591-3701. PMID: 39210723. DOI: 10.1093/eurheartj/ehae176. https://pubmed.ncbi.nlm.nih.gov/39210723/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Steinberg JS, Varma N, Cygankiewicz I, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Annals of Noninvasive Electrocardiology. 2017;22(3):e12447. PMID: 28480632. DOI: 10.1111/anec.12447. https://pubmed.ncbi.nlm.nih.gov/28480632/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Boriani G, Mei DA, Vitolo M, et al. The 2024 ESC guidelines on atrial fibrillation: essential updates for everyday clinical practice. Internal and Emergency Medicine. 2025;20(4):511-519. PMID: 40514614. DOI: 10.1007/s11739-025-03912-z. https://pubmed.ncbi.nlm.nih.gov/40514614/ ↩︎
Varma N, Cygankiewicz I, Turakhia MP, et al. 2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society. Circulation: Arrhythmia and Electrophysiology. 2021;14(2):e009236. PMID: 33573393. DOI: 10.1161/CIRCEP.120.009204. https://pubmed.ncbi.nlm.nih.gov/33573393/ ↩︎ ↩︎ ↩︎ ↩︎
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382-e482. PMID: 30586772. DOI: 10.1161/CIR.0000000000000628. https://pubmed.ncbi.nlm.nih.gov/30586772/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Abideen Asad ZU, Krishan S, Agarwal S. Effect of implantable loop recorder-based continuous rhythm monitoring on incident atrial fibrillation and stroke: An updated systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2024;21(12):1995-2002. PMID: 38848862. DOI: 10.1016/j.hrthm.2024.05.059. https://pubmed.ncbi.nlm.nih.gov/38848862/ ↩︎ ↩︎ ↩︎
Perez MV, Mahaffey KW, Hedlin H, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine. 2019;381(20):1909-1917. PMID: 31722151. DOI: 10.1056/NEJMoa1901183. https://pubmed.ncbi.nlm.nih.gov/31722151/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. New England Journal of Medicine. 2014;370(26):2478-2486. PMID: 24963567. DOI: 10.1056/NEJMoa1313600. https://pubmed.ncbi.nlm.nih.gov/24963567/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Edwards SJ, Wakefield V, Jhita T, et al. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. Health Technology Assessment. 2020;24(5):1-204. PMID: 31944175. DOI: 10.3310/hta24050. https://pubmed.ncbi.nlm.nih.gov/31944175/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(4):360-367. PMID: 35076659. DOI: 10.1001/jama.2021.23732. https://pubmed.ncbi.nlm.nih.gov/35076659/ ↩︎ ↩︎
Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. The Lancet. 2021;398(10310):1507-1516. PMID: 34469766. DOI: 10.1016/S0140-6736(21)01696-3. https://pubmed.ncbi.nlm.nih.gov/34469766/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Yousufuddin M, Jahangir A. In older patients at high risk for stroke, intensive AF screening with an implantable loop recorder did not reduce stroke. Annals of Internal Medicine. 2022. PMID: 34978859. https://pubmed.ncbi.nlm.nih.gov/34978859/ ↩︎ ↩︎
Xing LY, Diederichsen SZ, Højberg S, et al. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study. Circulation. 2023;147(24):1812-1822. PMID: 37061802. DOI: 10.1161/CIRCULATIONAHA.122.063273. https://pubmed.ncbi.nlm.nih.gov/37061802/ ↩︎ ↩︎ ↩︎ ↩︎
Vad OB, Diederichsen SZ, Xing LY, et al. Atrial Fibrillation Screening According to Genetic Risk: A Secondary Analysis of the Randomized LOOP Study. Journal of the American College of Cardiology. 2026. PMID: 41159983. DOI: 10.1016/j.jacc.2025.11.012. https://pubmed.ncbi.nlm.nih.gov/41159983/ ↩︎ ↩︎ ↩︎ ↩︎
Xing LY, Diederichsen SZ, Højberg S, et al. Systolic Blood Pressure and Effects of Screening for Atrial Fibrillation With Long-Term Continuous Monitoring (a LOOP Substudy). Hypertension. 2022;79(9):2069-2077. PMID: 35862138. DOI: 10.1161/HYPERTENSIONAHA.122.19318. https://pubmed.ncbi.nlm.nih.gov/35862138/ ↩︎ ↩︎ ↩︎ ↩︎
Spona DC, Frodi DM, Xing LY, et al. Effects of Atrial Fibrillation Screening According to Thyroid Function: Post Hoc Analysis of the Randomized LOOP Study. The Journal of Clinical Endocrinology & Metabolism. 2025. PMID: 39231015. DOI: 10.1210/clinem/dgae123. https://pubmed.ncbi.nlm.nih.gov/39231015/ ↩︎ ↩︎ ↩︎ ↩︎
Jung W, Zvereva V, Rillig A. How to use implantable loop recorders in clinical trials and hybrid therapy. Journal of Interventional Cardiac Electrophysiology. 2011;32(3):213-220. PMID: 21993595. DOI: 10.1007/s10840-011-9595-3. https://pubmed.ncbi.nlm.nih.gov/21993595/ ↩︎ ↩︎ ↩︎ ↩︎
Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018;320(2):146-155. PMID: 29998336. DOI: 10.1001/jama.2018.8102. https://pubmed.ncbi.nlm.nih.gov/29998336/ ↩︎ ↩︎
Nguyen KT, Yu J, Hedlin H, et al. Racial and Ethnic Representation and Study Engagement in a Siteless Digital Clinical Trial Using a Smartwatch: Findings From the Apple Heart Study. Mayo Clinic Proceedings: Digital Health. 2025;3(1):e00021. PMID: 40673279. DOI: 10.1016/j.mcpdig.2025.01.002. https://pubmed.ncbi.nlm.nih.gov/40673279/ ↩︎ ↩︎ ↩︎
Turakhia MP, Desai M, Hedlin H, et al. Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study. American Heart Journal. 2019;207:66-75. PMID: 30392584. DOI: 10.1016/j.ahj.2018.10.005. https://pubmed.ncbi.nlm.nih.gov/30392584/ ↩︎ ↩︎
Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. The Lancet. 2021;398(10310):1498-1506. PMID: 34469764. DOI: 10.1016/S0140-6736(21)01637-8. https://pubmed.ncbi.nlm.nih.gov/34469764/ ↩︎ ↩︎ ↩︎ ↩︎
Olsen FJ, Diederichsen SZ, Jørgensen PG, et al. Effects of Atrial Fibrillation Screening According to Echocardiographic Measures of Cardiac Structure and Function: A Post Hoc Analysis of the LOOP Randomized Clinical Trial. Journal of the American Heart Association. 2026. PMID: 41467399. DOI: 10.1161/JAHA.125.034567. https://pubmed.ncbi.nlm.nih.gov/41467399/ ↩︎ ↩︎ ↩︎
Choe WC, Passman RS, Brachmann J. A Comparison of Atrial Fibrillation Monitoring Strategies After Cryptogenic Stroke (from the Cryptogenic Stroke and Underlying AF Trial). The American Journal of Cardiology. 2015;116(6):957-961. PMID: 26183793. DOI: 10.1016/j.amjcard.2015.06.012. https://pubmed.ncbi.nlm.nih.gov/26183793/ ↩︎
Xing LY, Diederichsen SZ, Højberg S, et al. Screening for atrial fibrillation to prevent stroke in elderly individuals with or without preexisting cardiovascular disease: A post hoc analysis of the randomized LOOP Study. International Journal of Cardiology. 2023;370:203-210. PMID: 36328113. DOI: 10.1016/j.ijcard.2022.10.158. https://pubmed.ncbi.nlm.nih.gov/36328113/ ↩︎
Diederichsen SZ, Haugan KJ, Køber L, et al. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial. American Heart Journal. 2017;187:115-122. PMID: 28454796. DOI: 10.1016/j.ahj.2017.02.027. https://pubmed.ncbi.nlm.nih.gov/28454796/ ↩︎
Diederichsen SZ, Frederiksen KS, Xing LY, et al. Severity and Etiology of Incident Stroke in Patients Screened for Atrial Fibrillation vs Usual Care and the Impact of Prior Stroke: A Post Hoc Analysis of the LOOP Randomized Clinical Trial. JAMA Neurology. 2022;79(10):1016-1024. PMID: 36036546. DOI: 10.1001/jamaneurol.2022.2694. https://pubmed.ncbi.nlm.nih.gov/36036546/ ↩︎
Kongebro EK, Kronborg C, Xing LY, et al. Effects of population-based screening for atrial fibrillation on quality of life. European Journal of Internal Medicine. 2025. PMID: 39800594. DOI: 10.1016/j.ejim.2025.04.012. https://pubmed.ncbi.nlm.nih.gov/39800594/ ↩︎
Xing LY, Diederichsen SZ, Højberg S, et al. Electrocardiographic Morphology-Voltage-P-Wave-Duration (MVP) Score to Select Patients for Continuous Atrial Fibrillation Screening to Prevent Stroke. The American Journal of Cardiology. 2023;205:224-231. PMID: 37666019. DOI: 10.1016/j.amjcard.2023.08.029. https://pubmed.ncbi.nlm.nih.gov/37666019/ ↩︎
Xing LY, Diederichsen SZ, Højberg S, et al. Electrocardiographic markers of subclinical atrial fibrillation detected by implantable loop recorder: insights from the LOOP Study. Europace. 2023;25(5):euad122. PMID: 37068888. DOI: 10.1093/europace/euad122. https://pubmed.ncbi.nlm.nih.gov/37068888/ ↩︎
Turnbull S, Gupta A, Garikapati K, et al. Smartwatch-Based Heart Rate Detection in Atrial, Ventricular and Pulseless Arrhythmias. Heart, Lung & Circulation. 2026. PMID: 42350250. DOI: 10.1016/j.hlc.2025.10.015. https://pubmed.ncbi.nlm.nih.gov/42350250/ ↩︎ ↩︎ ↩︎
Kim SE, Khawaja M, Kim JA, et al. Detection of atrial fibrillation in real world setting in patients with cryptogenic stroke and an implantable loop recorder. Pacing and Clinical Electrophysiology. 2023;46(7):643-649. PMID: 37323035. DOI: 10.1111/pace.14757. https://pubmed.ncbi.nlm.nih.gov/37323035/ ↩︎
Engdahl J, Holmén A, Svennberg E, et al. Geographic and socio-demographic differences in uptake of population-based screening for atrial fibrillation: The STROKESTOP I study. International Journal of Cardiology. 2016;222:817-822. PMID: 27505329. DOI: 10.1016/j.ijcard.2016.08.016. https://pubmed.ncbi.nlm.nih.gov/27505329/ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Han D, Ding EY, Cho C, et al. A Smartwatch System for Continuous Monitoring of Atrial Fibrillation in Older Adults After Stroke or Transient Ischemic Attack: Application Design Study. JMIR Cardio. 2023;7:e37613. PMID: 36780211. DOI: 10.2196/37613. https://pubmed.ncbi.nlm.nih.gov/36780211/ ↩︎ ↩︎